BVS 857

Drug Profile

BVS 857

Alternative Names: BVS-857

Latest Information Update: 21 Jul 2016

Price : $50

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Burns; Spinal muscular atrophy
  • No development reported Insulin resistance

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Insulin-resistance in USA (Parenteral)
  • 01 Apr 2016 Novartis completes a phase II trial in Spinal muscular atrophy in USA, Denmark, Germany, Italy (SC, IV) (NCT02024932)
  • 25 Jan 2016 Phase-II clinical trials in Spinal muscular atrophy in Denmark and Germany (IV & SC) (NCT02024932)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top